The Tisch Cancer Institute at Mount Sinai | Strategic Alliance Partners

April 02, 2024

Dmitriy Zamarin, MD, PhD, discusses the most recent advances in gynecologic cancer management, particularly in endometrial cancer.

March 29, 2024

Matthew Galsky, MD, discusses the significance of the FDA approval of frontline nivolumab plus chemotherapy patients with metastatic urothelial carcinoma.

March 29, 2024

Dmitriy Zamarin, MD, PhD, highlights key changes and ongoing research across the endometrial, ovarian, and cervical cancer realms.

March 19, 2024

Joshua Richter, MD, discusses ongoing or upcoming research with bispecific antibodies in relapsed/refractory multiple myeloma.

March 19, 2024

In a trial led by the Icahn School of Medicine at Mount Sinai, rusfertide demonstrated the ability to control the overproduction of RBCs in polycythemia vera.

March 14, 2024

A study sheds light on how immune genetics influence lung cancer risk, potentially paving the way for enhanced prevention strategies and screening.

February 27, 2024

Rusfertide displayed activity in phlebotomy-dependent polycythemia vera.

February 23, 2024

The FDA has determined that sufficient criteria have been met to withdraw the approval for melphalan flufenamide in patients with multiple myeloma.

February 15, 2024

Matthew Galsky, MD, discusses the significance of the FDA approval of enfortumab vedotin plus pembrolizumab as a first-line regimen in urothelial cancer.

February 12, 2024

Matthew Galsky, MD, discusses the FDA approval of enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.

February 12, 2024

Dr Galsky discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer.

January 11, 2024

John Mascarenhas, MD, discusses the potential advantages of utilizing selinexor with ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

December 18, 2023

Diagnosing early-stage lung cancer with low-dose computed tomography screening drastically improves the survival rate of cancer patients over a 20-year period, according to a large-scale international study being presented by Mount Sinai researchers at the annual meeting of the Radiological Society of North America.

December 16, 2023

Groundbreaking study opens new avenues for future treatment and diagnosis.

December 07, 2023

The Department of Immunology and Immunotherapy and the Icahn Genomics Institute at the Icahn School of Medicine at Mount Sinai have been awarded a $5 million grant from the National Cancer Institute of the National Institutes of Health to establish a state-of-the-art center dedicated to the discovery and development of cutting-edge targets for cancer therapy.

December 01, 2023

Marina Kremyanskaya, MD, PhD, discusses disease and patient characteristics that influence the choice between hydroxyurea and interferon therapy for patients with polycythemia vera or essential thrombocythemia.

December 01, 2023

Joseph A. Sparano, MD, FACP, discusses developments in breast cancer diagnosis and treatment.

November 21, 2023

Joshua Richter, MD, discusses how bispecific antibodies fit into the current treatment armamentarium for patients with multiple myeloma, highlighting his presentation from the 41st Annual CFS®.

November 21, 2023

Joshua Richter, MD, provides an overview of the current state of bispecific antibodies in multiple myeloma, discusses ongoing investigations of these agents, and expands on their unique toxicities and the need for proactive management.

November 18, 2023

Investigators at the Icahn School of Medicine at Mount Sinai have designed an innovative RNA-based strategy to activate dendritic cells—which play a key role in immune response—that eradicated tumors and prevented their recurrence in mouse models of melanoma.